drugset / Trial / NCT01799590

Continuous Treatment Study of Topiramate in Migraine Participants

NCT01799590

Phase 2 Completed 296 enrolled Janssen Pharmaceutical K.K.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of topiramate in participants with migraine (type of severe headache that occurs periodically and is often associated with nausea, vomiting and constipation or diarrhea) who completed the JNS019-JPN-02 study.

Timeline

Start
2007-08
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Topiramate Small molecule 50 mg
Subject Topiramate Small molecule 100 mg

Indications